Tequin, one of the brand names for the pharmaceutical product Gatifloxacin, was introduced to the U.S. market by Bristol-Myers Squibb in 1999. The drug, an antibiotic, was prescribed primarily for the treatment of respiratory tract infections.
In 2006, a report in the New England Journal of Medicine alleged that Tequin had been found to put users at an elevated risk for dysglycemia, a blood sugar metabolism disorder that may manifest as either hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar). Initially, Bristol-Myers Squibb notified health care providers that product warnings would be enhanced. However, the company subsequently opted to terminate the manufacture of Tequin. The product is now available only as treatment for eye conditions, in the form of an eye drop.
If you experienced side effects after being prescribed Tequin, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Latest Articles
Rethinking Marijuana-Related Crimes
In recent years, the way we have thought about marijuana, its use and its legality, have changed. Me…
Read More 11 Feb 2019, MondayWhat You Need to Know about Flood Insurance
In the past few years, cities have been battered by hurricanes and tropical storms, resulting in inj…
Read More 04 Feb 2019, MondayThree Common Types of Temporary Visas
With all the controversy swirling around immigration these days, you’ve probably heard discussions…
Read More 28 Jan 2019, Monday
